Cancer therapy company Lantern Pharma Inc (NASDAQ: LTRN) announced on Monday that it has received FDA clearance for its investigational new drug (IND) application for LP-284, targeting the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL). The Phase 1 trial for LP-284 is set to begin enrollment in Q4 2023.
LP-284 is designed to preferentially damage cancer cells with mutations in DNA damage repair pathways.
NHL, a haematological malignancy, affects around 500,000 people globally annually. Despite advances in treatment, a significant percentage of patients relapse, making LP-284's estimated global market potential of USD4bn a significant opportunity for Lantern Pharma.
Lantern Pharma is an AI-driven company that aims to accelerate oncology drug discovery and development using its RADR platform, cutting costs and timelines. The company's growing pipeline, with a combined annual market potential of over USD15bn, includes therapies for multiple cancer indications.
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Evommune signs strategic collaboration with Maruho Co
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Sanofi granted Priority Review for EoE treatment in young children
Valneva secures USD32m IXIARO vaccine contract with US DoD
Sanofi's ALTUVIIIO gains Japanese approval as haemophilia A factor VIII therapy
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Mabwell's 9MW3011 receives US FDA Fast Track Designation
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis